MA38478A1 - Anticorps anti-pac1 humains - Google Patents

Anticorps anti-pac1 humains

Info

Publication number
MA38478A1
MA38478A1 MA38478A MA38478A MA38478A1 MA 38478 A1 MA38478 A1 MA 38478A1 MA 38478 A MA38478 A MA 38478A MA 38478 A MA38478 A MA 38478A MA 38478 A1 MA38478 A1 MA 38478A1
Authority
MA
Morocco
Prior art keywords
antibodies
pac1
antigen
binding fragments
human anti
Prior art date
Application number
MA38478A
Other languages
English (en)
Inventor
Cen Xu
Agnes Eva Hamburger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA38478A1 publication Critical patent/MA38478A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

L'invention concerne des anticorps et des fragments de liaison à un antigène de ceux-ci qui se lient à pac1 humain. L'invention concerne des acides nucléiques codant pour les anticorps et des fragments de liaison à un antigène de ceux-ci, des vecteurs, et des cellules codant pour ceux-ci. Les anticorps et fragments de liaison à un antigène de ceux-ci peuvent inhiber la liaison de pac1 à pacap et sont utiles dans un nombre de troubles associés à pac1, comprenant le traitement et/ou la prévention de troubles de maux de tête, comprenant la migraine et l'algie vasculaire de la face.
MA38478A 2013-03-15 2014-03-14 Anticorps anti-pac1 humains MA38478A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792678P 2013-03-15 2013-03-15
PCT/US2014/029128 WO2014144632A2 (fr) 2013-03-15 2014-03-14 Anticorps anti-pac1 humains

Publications (1)

Publication Number Publication Date
MA38478A1 true MA38478A1 (fr) 2017-11-30

Family

ID=50439531

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38478A MA38478A1 (fr) 2013-03-15 2014-03-14 Anticorps anti-pac1 humains

Country Status (24)

Country Link
US (7) US9676851B2 (fr)
EP (2) EP2970470B1 (fr)
JP (3) JP6283408B2 (fr)
KR (1) KR102215405B1 (fr)
CN (1) CN105143267B (fr)
AP (1) AP2015008732A0 (fr)
AR (1) AR095611A1 (fr)
AU (2) AU2014228924B2 (fr)
CA (1) CA2906737C (fr)
CL (1) CL2015002750A1 (fr)
CR (1) CR20150575A (fr)
EA (1) EA032830B1 (fr)
ES (1) ES2770976T3 (fr)
HK (2) HK1218554A1 (fr)
IL (2) IL241382A0 (fr)
MA (1) MA38478A1 (fr)
MX (1) MX2015013181A (fr)
PE (1) PE20151923A1 (fr)
PH (1) PH12015502126A1 (fr)
SG (1) SG11201507416WA (fr)
TN (1) TN2015000425A1 (fr)
TW (2) TW201902931A (fr)
UY (1) UY35483A (fr)
WO (1) WO2014144632A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044224A1 (fr) 2014-09-15 2016-03-24 Amgen Inc. Protéines de liaison antigéniques bispécifiques anti-récepteur cgrp/récepteur pac1 et leurs utilisations
EP3283169A4 (fr) 2015-04-16 2019-03-20 Alder Biopharmaceuticals, Inc. Utilisation d'anticorps anti-pacap et de leurs fragments de liaison à l'antigène pour le traitement, la prévention ou l'inhibition de la photophobie
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
AR113022A1 (es) * 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
CN111164101A (zh) * 2017-10-04 2020-05-15 安进公司 甲状腺素视黄质运载蛋白免疫球蛋白融合体
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения
CA3096374A1 (fr) 2018-04-12 2019-10-17 Amgen Inc. Procedes de preparation de compositions proteiques stables
EP3990493A1 (fr) 2019-06-28 2022-05-04 Amgen Inc. Protéines de liaison à l'antigène bispécifiques anti-récepteur pac1/anti-récepteur cgrp
WO2023015298A1 (fr) * 2021-08-06 2023-02-09 Amgen Inc. Isolement de protéine thérapeutique
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
WO1991014786A1 (fr) 1990-03-17 1991-10-03 Takeda Chemical Industries, Ltd. Anticorps de peptide activateur de cyclase d'adenylate pituitaire (pacap), hybridome et analyse de pacap
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2105984C (fr) 1991-03-11 2002-11-26 Milton J. Cormier Clonage et expression de la luciferase de renilla
AU2249592A (en) 1991-06-14 1993-01-12 Dnx Corporation Production of human hemoglobin in transgenic pigs
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
WO1994010308A1 (fr) 1992-10-23 1994-05-11 Immunex Corporation Procede de preparation de proteines oligomeres solubles
EP0618291A3 (fr) 1993-02-26 1997-12-03 Takeda Chemical Industries, Ltd. Protéine réceptrice-PACAP, méthode pour la préparation de cette protéine et l'utilisation de celle-ci
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6146826A (en) 1993-09-10 2000-11-14 The Trustees Of Columbia University In The City Of New York Green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
AU741076B2 (en) 1996-12-12 2001-11-22 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DE69938293T2 (de) 1998-03-27 2009-03-12 Bruce J. Beverly Hills Bryan Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
ES2335827T3 (es) 1998-07-20 2010-04-05 Ipsen Pharma Analogos peptidos de pacap.
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US20020155533A1 (en) 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2005056606A2 (fr) * 2003-12-03 2005-06-23 Xencor, Inc Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
WO2004046330A2 (fr) * 2002-11-15 2004-06-03 Morphotek, Inc. Methodes de generation d'une quantite elevee d'anticorps a partir d'hybridomes crees par immunisation in vitro
EP1583550A2 (fr) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition de la signalisation pacap dans la prevention et le traitement de la thrombocytopenie
US20050129687A1 (en) 2003-11-03 2005-06-16 University Of Vermont And State Agricultural College Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
JP2007522118A (ja) 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2620364A1 (fr) 2005-08-26 2007-03-01 David C. Yeomans Methodes de traitement des maux de tete par administration d'oxytocine
WO2008018472A1 (fr) * 2006-08-08 2008-02-14 Kyoto University Nouvel anticorps monoclonal et son utilisation
WO2009003489A1 (fr) 2007-07-02 2009-01-08 Natimmune A/S POLYPEPTIDES DE LIAISON À L'ÉPITOPE CaOU-1
WO2009033489A2 (fr) 2007-09-11 2009-03-19 Glostrup Hospital Traitement de la migraine et de céphalées par des inhibiteurs sélectifs de pac1
CN101434649B (zh) 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
NZ597763A (en) 2009-07-27 2014-07-25 Nocicepta Llc Methods for treatment of pain
WO2011035456A1 (fr) * 2009-09-25 2011-03-31 上海抗体药物国家工程研究中心有限公司 Procédé d'acquisition de protéines présentant une forte affinité au moyen d'une technique de conception assistée par ordinateur
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
WO2011118739A1 (fr) * 2010-03-26 2011-09-29 協和発酵キリン株式会社 Nouvel anticorps ayant un site de modification introduit dans celui-ci, et fragment d'anticorps
JP5972915B2 (ja) * 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
CN102936303A (zh) * 2011-08-15 2013-02-20 沈阳欧陆科技发展有限公司 一种高氯含量的氯化聚氯乙烯树脂的合成方法
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
MY181743A (en) 2012-05-21 2021-01-06 Genentech Inc Methods for improving safety of blood-brain barrier transport
WO2013180295A1 (fr) 2012-06-01 2013-12-05 日本電信電話株式会社 Procédé de traitement de transfert de paquets et dispositif de traitement de transfert de paquets
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CL2015002750A1 (es) 2016-03-04
BR112015023429A2 (pt) 2017-11-28
CR20150575A (es) 2016-01-06
JP2019024501A (ja) 2019-02-21
IL241382A0 (en) 2015-11-30
JP6443870B2 (ja) 2018-12-26
IL262804A (en) 2018-12-31
US10294298B2 (en) 2019-05-21
AR095611A1 (es) 2015-10-28
JP6283408B2 (ja) 2018-02-21
US9365653B2 (en) 2016-06-14
CN105143267B (zh) 2020-06-26
HK1219958A1 (zh) 2017-04-21
AU2019204980A1 (en) 2019-08-01
KR102215405B1 (ko) 2021-02-10
AU2014228924A1 (en) 2015-10-01
EP2970470A2 (fr) 2016-01-20
TW201902931A (zh) 2019-01-16
WO2014144632A3 (fr) 2014-11-20
PE20151923A1 (es) 2016-01-14
US10472417B2 (en) 2019-11-12
EA201591791A1 (ru) 2016-03-31
US20180094055A1 (en) 2018-04-05
WO2014144632A8 (fr) 2015-12-30
US20200172614A1 (en) 2020-06-04
UY35483A (es) 2014-08-29
US9676851B2 (en) 2017-06-13
AU2014228924B2 (en) 2019-04-18
US20180362645A1 (en) 2018-12-20
SG11201507416WA (en) 2015-10-29
TN2015000425A1 (en) 2017-01-03
ES2770976T3 (es) 2020-07-06
TWI636064B (zh) 2018-09-21
US9822178B2 (en) 2017-11-21
CN105143267A (zh) 2015-12-09
TW201522375A (zh) 2015-06-16
US20160251432A1 (en) 2016-09-01
CA2906737A1 (fr) 2014-09-18
JP2016514458A (ja) 2016-05-23
WO2014144632A2 (fr) 2014-09-18
US20150010560A1 (en) 2015-01-08
JP2018076373A (ja) 2018-05-17
HK1218554A1 (zh) 2017-02-24
BR112015023429A8 (pt) 2018-01-23
US20160039939A1 (en) 2016-02-11
EP3683237A1 (fr) 2020-07-22
AU2014228924A9 (en) 2016-06-16
US10793631B2 (en) 2020-10-06
EP2970470B1 (fr) 2019-12-04
AP2015008732A0 (en) 2015-09-30
PH12015502126A1 (en) 2016-01-25
US10053507B2 (en) 2018-08-21
MX2015013181A (es) 2015-12-11
CA2906737C (fr) 2023-08-15
US20170247451A1 (en) 2017-08-31
EA032830B1 (ru) 2019-07-31
KR20150128982A (ko) 2015-11-18

Similar Documents

Publication Publication Date Title
MA38478A1 (fr) Anticorps anti-pac1 humains
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA38930A1 (fr) Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)
MA39342B2 (fr) Anticorps il -21
MA39096B1 (fr) Anticorps spécifiques à fcrn
PH12014501985A1 (en) Il-17 antibody formulation
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
MA39336A1 (fr) Molécules d'anticorps anti-lag-3 et leurs utilisations
MA38501A1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA56083B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
MA39221B1 (fr) Molécules d'anticorps anti-tim-3 et leurs utilisations